Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

U.S. Senate Investigation of Avandia

According to a Senate Finance Committee inquiry, GlaxoSmithKline, the manufacturer of the diabetes drug Avandia, failed to publish studies that found serious health risks associated with Avandia in a timely manner and actively promoted the drug despite the known safety concerns. Documents obtained by the committee showed that, as far back as 2000, GSK executives sought to downplay scientific findings which raised questions about Avandia’s safety. Additionally, the committee found Avandia was part of a “ghostwriting campaign,” a practice by which pharmaceutical companies disguise their role in publishing articles promoting their products in medical journals under the byline of purportedly independent doctors or scientists. In September 2010, the U.S. Food and Drug Administration severely restricted the sale of Avandia.

Misconduct Type
Health
Enforcement Agency
Congress
Contracting Party
None
Court Type
N/A
Disposition
Investigative Finding
Date of Senate Letter to FDA
7/12/2010
Contractors Involved Penalty
Total
GlaxoSmithKline $0
Further Information Released
Senate Finance Committee Letter to FDA 8/10/2010
Senate Finance Committee Press Release 8/10/2010

Federal Contractor Misconduct Database